BRPI0517253A - compostos e composições como moduladores de trajetória de ouriço - Google Patents

compostos e composições como moduladores de trajetória de ouriço

Info

Publication number
BRPI0517253A
BRPI0517253A BRPI0517253-5A BRPI0517253A BRPI0517253A BR PI0517253 A BRPI0517253 A BR PI0517253A BR PI0517253 A BRPI0517253 A BR PI0517253A BR PI0517253 A BRPI0517253 A BR PI0517253A
Authority
BR
Brazil
Prior art keywords
hedgehog
compositions
compounds
modulators
trajectory
Prior art date
Application number
BRPI0517253-5A
Other languages
English (en)
Inventor
Xu Wu
Sheng Ding
Peter G Schultz
Original Assignee
Irm Llc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc
Publication of BRPI0517253A publication Critical patent/BRPI0517253A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS E COMPOSIçõES COMO MODULADORES DE TRAJETóRIA DE OURIçO. A presente invenção refere-se a um método para a modulação da atividade de trajetória de sinalização de ouriço. Em particular, a invenção provê um método para a inibição de estados de crescimento aberrante que resultam de fenótipos tais como perda de função de Ptc, ganho de função de ouriço, ganho de função suavizada ou ganho de função de Gli, compreendendo o contato de uma célula com uma quantidade suficiente de um composto da fórmula I.
BRPI0517253-5A 2004-10-28 2005-10-28 compostos e composições como moduladores de trajetória de ouriço BRPI0517253A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62344404P 2004-10-28 2004-10-28
PCT/US2005/039442 WO2006050351A2 (en) 2004-10-28 2005-10-28 Compounds and compositions as hedgehog pathway modulators

Publications (1)

Publication Number Publication Date
BRPI0517253A true BRPI0517253A (pt) 2008-10-07

Family

ID=36319759

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517253-5A BRPI0517253A (pt) 2004-10-28 2005-10-28 compostos e composições como moduladores de trajetória de ouriço

Country Status (11)

Country Link
US (1) US20090209573A1 (pt)
EP (1) EP1804803A4 (pt)
JP (1) JP2008518954A (pt)
KR (1) KR20070083836A (pt)
CN (1) CN101083996A (pt)
AU (1) AU2005302279A1 (pt)
BR (1) BRPI0517253A (pt)
CA (1) CA2583812A1 (pt)
MX (1) MX2007005125A (pt)
RU (1) RU2007119637A (pt)
WO (1) WO2006050351A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50521B (sr) 2004-01-12 2010-05-07 Applied Research Systems Ars Holding N.V. Derivati tiazola i njihova upotreba
ITVA20060041A1 (it) * 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
PE20080948A1 (es) 2006-07-25 2008-09-10 Irm Llc Derivados de imidazol como moduladores de la senda de hedgehog
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
PE20090806A1 (es) 2007-04-18 2009-06-27 Merck & Co Inc Derivados de triazol que son antagonistas de smo
WO2009051909A1 (en) * 2007-10-16 2009-04-23 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr cellular processing and uses thereof
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2738868C (en) 2008-10-01 2017-01-17 Novartis Ag Smoothened antagonism for the treatment of hedgehog pathway-related disorders
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
JP2013516480A (ja) 2010-01-07 2013-05-13 セレクサゲン セラピューティクス，インク． ヘッジホッグ阻害剤
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
JP6115962B2 (ja) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ．ベー． １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
EP2925363A4 (en) 2012-11-29 2016-11-09 Strasspharma Llc METHOD FOR MODULATING FOLLICLE-STIMULATING HORMONACTIVITY
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
WO2019062657A1 (zh) * 2017-09-30 2019-04-04 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
EP4185279A4 (en) 2020-07-24 2024-05-01 Secura Bio, Inc. TREATING CANCER WITH PI3-KINASE ISOFORM MODULATORS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SK6652000A3 (en) * 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
CA2397661C (en) * 2000-03-01 2012-01-03 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
GB2361236B (en) * 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
EP1277754B8 (en) * 2000-04-27 2005-09-28 Astellas Pharma Inc. Imidazopyridine derivatives
GB0021726D0 (en) * 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002034748A1 (fr) * 2000-10-24 2002-05-02 Sankyo Company, Limited Derives d'imidazopyridine
CA2460909A1 (en) * 2001-09-28 2003-04-10 Cyclacel Limited N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds
AU2003231032B2 (en) * 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
JP2003313126A (ja) * 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
KR100530988B1 (ko) * 2003-03-14 2005-11-28 한국과학기술원 봉입체 결합 단백질을 코딩하는 유전자를 결핍시키거나 증폭시켜 목적 단백질을 제조하는 방법
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
RS50521B (sr) * 2004-01-12 2010-05-07 Applied Research Systems Ars Holding N.V. Derivati tiazola i njihova upotreba
GB0411791D0 (en) * 2004-05-26 2004-06-30 Cyclacel Ltd Compounds

Also Published As

Publication number Publication date
EP1804803A2 (en) 2007-07-11
AU2005302279A1 (en) 2006-05-11
KR20070083836A (ko) 2007-08-24
EP1804803A4 (en) 2008-07-30
US20090209573A1 (en) 2009-08-20
RU2007119637A (ru) 2008-12-10
CA2583812A1 (en) 2006-05-11
MX2007005125A (es) 2007-07-04
WO2006050351A3 (en) 2007-02-22
CN101083996A (zh) 2007-12-05
JP2008518954A (ja) 2008-06-05
WO2006050351A2 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
BRPI0711333A2 (pt) compostos e composições como moduladores da via hedgehog
BRPI0917936A2 (pt) Moduladores de via hedgehog
MX2007005125A (es) Compuestos y composiciones como moduladores de la senda de hedgehog.
BR112013000868A2 (pt) derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4
UA97258C2 (ru) Гербицидная композиция, применение ее для контроля сорняков в сельскохозяйственных культурах и способ контроля сорняков
WO2009027820A3 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2008014291A3 (en) Compounds and compositions as hedgehog signaling pathway modulators
NO20092569L (no) Inhibitorer av Akt-aktivitet
UY32313A (es) Composiciones herbicidas que contienen compuestos de benzoilpirazol y otro compuesto herbicida
PH12012502061A1 (en) Active compound combinations
UA90209C2 (ru) Фунгицидная композиция, способ борьбы с заболеваниями полезных растений и способ защиты товаров
WO2007109330A3 (en) S1p receptor modulating compounds
EA201001229A1 (ru) Композиция для повышения жизнеспособности растений
WO2010001169A3 (en) Chemical compounds 251
ATE487380T1 (de) Verwendung einer verbindung mit monogalactosyldiacylglycerol-synthase- hemmungsaktivität als herbizid oder algizid, herbizid- und algizidzusammensetzungen
MX2010007952A (es) Arilpirrolinas insecticidas.
BRPI0915589B8 (pt) combinação herbicida sinérgica de clomazone e petoxamida
WO2009133374A3 (en) Antisapstain compositions comprising a haloalkynyl compound, an azole and an unsaturated acid
WO2010034015A3 (en) Modulating the alternative complement pathway
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
EA200901610A1 (ru) Производные бифенилкарбоксамида в качестве модуляторов пути хеджхок
MX2009007206A (es) Mezclas de pesticidas.
EA200700286A1 (ru) Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов
EA201071369A1 (ru) Композиции для лечения выпадения волос
GT200700057A (es) Nuevos derivados de piridazina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.